269 related articles for article (PubMed ID: 25337704)
1. Pain related channels are differentially expressed in neuronal and non-neuronal cells of glabrous skin of fabry knockout male mice.
Lakomá J; Rimondini R; Donadio V; Liguori R; Caprini M
PLoS One; 2014; 9(10):e108641. PubMed ID: 25337704
[TBL] [Abstract][Full Text] [Related]
2. Increased expression of Trpv1 in peripheral terminals mediates thermal nociception in Fabry disease mouse model.
Lakomá J; Rimondini R; Ferrer Montiel A; Donadio V; Liguori R; Caprini M
Mol Pain; 2016; 12():. PubMed ID: 27531673
[TBL] [Abstract][Full Text] [Related]
3. L-Acetylcarnitine causes analgesia in mice modeling Fabry disease by up-regulating type-2 metabotropic glutamate receptors.
Formaggio F; Rimondini R; Delprete C; Scalia L; Merlo Pich E; Liguori R; Nicoletti F; Caprini M
Mol Pain; 2022; 18():17448069221087033. PubMed ID: 35255745
[TBL] [Abstract][Full Text] [Related]
4. Characterization of small fiber pathology in a mouse model of Fabry disease.
Hofmann L; Hose D; Grießhammer A; Blum R; Döring F; Dib-Hajj S; Waxman S; Sommer C; Wischmeyer E; Üçeyler N
Elife; 2018 Oct; 7():. PubMed ID: 30328411
[TBL] [Abstract][Full Text] [Related]
5. Cardiac manifestations of Fabry disease in G3Stg/GlaKO and GlaKO mouse models-Translation to Fabry disease patients.
Kugadas A; Artoni P; Ruangsiriluk W; Zhao M; Boukharov N; Islam R; Volfson D; Derakhchan K
PLoS One; 2024; 19(5):e0304415. PubMed ID: 38820517
[TBL] [Abstract][Full Text] [Related]
6. α-Galactosidase A knockout mice: progressive organ pathology resembles the type 2 later-onset phenotype of Fabry disease.
Bangari DS; Ashe KM; Desnick RJ; Maloney C; Lydon J; Piepenhagen P; Budman E; Leonard JP; Cheng SH; Marshall J; Thurberg BL
Am J Pathol; 2015 Mar; 185(3):651-65. PubMed ID: 25553976
[TBL] [Abstract][Full Text] [Related]
7. Altered globotriaosylceramide accumulation and mucosal neuronal fiber density in the colon of the Fabry disease mouse model.
Masotti M; Delprete C; Dothel G; Donadio V; Rimondini R; Politei JM; Liguori R; Caprini M
Neurogastroenterol Motil; 2019 Mar; 31(3):e13529. PubMed ID: 30609268
[TBL] [Abstract][Full Text] [Related]
8. Enhanced thrombospondin-1 causes dysfunction of vascular endothelial cells derived from Fabry disease-induced pluripotent stem cells.
Do HS; Park SW; Im I; Seo D; Yoo HW; Go H; Kim YH; Koh GY; Lee BH; Han YM
EBioMedicine; 2020 Feb; 52():102633. PubMed ID: 31981984
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive and differential long-term characterization of the alpha-galactosidase A deficient mouse model of Fabry disease focusing on the sensory system and pain development.
Üçeyler N; Biko L; Hose D; Hofmann L; Sommer C
Mol Pain; 2016; 12():. PubMed ID: 27145802
[TBL] [Abstract][Full Text] [Related]
10. Dysregulation of Immune Response Mediators and Pain-Related Ion Channels Is Associated with Pain-like Behavior in the GLA KO Mouse Model of Fabry Disease.
Spitzel M; Wagner E; Breyer M; Henniger D; Bayin M; Hofmann L; Mauceri D; Sommer C; Üçeyler N
Cells; 2022 May; 11(11):. PubMed ID: 35681422
[TBL] [Abstract][Full Text] [Related]
11. Endothelial Cell Dysfunction and Hypoxia as Potential Mediators of Pain in Fabry Disease: A Human-Murine Translational Approach.
Klug K; Spitzel M; Hans C; Klein A; Schottmann NM; Erbacher C; Üçeyler N
Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37895103
[TBL] [Abstract][Full Text] [Related]
12. Anderson-Fabry disease: a multiorgan disease.
Tuttolomondo A; Pecoraro R; Simonetta I; Miceli S; Pinto A; Licata G
Curr Pharm Des; 2013; 19(33):5974-96. PubMed ID: 23448451
[TBL] [Abstract][Full Text] [Related]
13. Affective and cognitive behavior in the alpha-galactosidase A deficient mouse model of Fabry disease.
Hofmann L; Karl F; Sommer C; Üçeyler N
PLoS One; 2017; 12(6):e0180601. PubMed ID: 28662189
[TBL] [Abstract][Full Text] [Related]
14. Stratification of Fabry mutations in clinical practice: a closer look at α-galactosidase A-3D structure.
Rickert V; Wagenhäuser L; Nordbeck P; Wanner C; Sommer C; Rost S; Üçeyler N
J Intern Med; 2020 Nov; 288(5):593-604. PubMed ID: 32583479
[TBL] [Abstract][Full Text] [Related]
15. Development of a model system for neuronal dysfunction in Fabry disease.
Kaneski CR; Brady RO; Hanover JA; Schueler UH
Mol Genet Metab; 2016 Sep; 119(1-2):144-50. PubMed ID: 27471012
[TBL] [Abstract][Full Text] [Related]
16. Globotriaosylceramide-induced reduction of K
Rickert V; Kramer D; Schubert AL; Sommer C; Wischmeyer E; Üçeyler N
Exp Neurol; 2020 Feb; 324():113134. PubMed ID: 31778662
[TBL] [Abstract][Full Text] [Related]
17. Alteration of proteomic profiles in PBMC isolated from patients with Fabry disease: preliminary findings.
Cigna D; D'Anna C; Zizzo C; Francofonte D; Sorrentino I; Colomba P; Albeggiani G; Armini A; Bianchi L; Bini L; Duro G
Mol Biosyst; 2013 Jun; 9(6):1162-8. PubMed ID: 23385635
[TBL] [Abstract][Full Text] [Related]
18. Non-clinical evaluation of JR-051 as a biosimilar to agalsidase beta for the treatment of Fabry disease.
Morimoto H; Ito Y; Yoden E; Horie M; Tanaka N; Komurasaki Y; Yamamoto R; Mihara K; Minami K; Hirato T
Mol Genet Metab; 2018 Sep; 125(1-2):153-160. PubMed ID: 30054149
[TBL] [Abstract][Full Text] [Related]
19. Ion channels and pain in Fabry disease.
Weissmann C; Albanese AA; Contreras NE; Gobetto MN; Castellanos LCS; Uchitel OD
Mol Pain; 2021; 17():17448069211033172. PubMed ID: 34284652
[TBL] [Abstract][Full Text] [Related]
20. Fabry Disease: Molecular Basis, Pathophysiology, Diagnostics and Potential Therapeutic Directions.
Kok K; Zwiers KC; Boot RG; Overkleeft HS; Aerts JMFG; Artola M
Biomolecules; 2021 Feb; 11(2):. PubMed ID: 33673160
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]